AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease

2024年05月24日 16:48:38

打印 放大 缩小

Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression

AC Immune to receive upfront payment of $100 million upon closing and be eligible for an option exercise fee and additional potential milestones of up to approximately $2.1 billion

AC Immune to host conference call and webcast today at 8:30 a.m. ET

OSAKA, Japan & CAMBRIDGE, Mass & LAUSANNE, Switzerland--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAKand AC Immune SA (NASDAQ: ACIU) today announced an exclusive, worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for the treatment of Alzheimer’s disease.

ACI-24.060 is an anti-Abeta active immunotherapy candidate designed to induce a robust antibody response against the toxic forms of Abeta believed to drive plaque formation and Alzheimer’s disease progression. By inducing plaque clearance and efficiently inhibiting plaque formation in the brain, ACI-24.060 has the potential to delay or slow Alzheimer’s disease progression. ACI-24.060 is being investigated in the ongoing ABATE randomized, double-blind, placebo-controlled Phase 1b/2 trial to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of the investigational immunotherapy in subjects with prodromal Alzheimer’s disease and in adults with Down syndrome.

“As pioneers in the field of active immunotherapy, we are developing an innovative approach that could change the treatment paradigm for Alzheimer’s disease and address the multifaceted burden that patients and the broader community face. We believe the maximum impact of ACI-24.060 can best be realized by partnering with Takeda at this critical juncture in its development, which will help us move rapidly into Phase 3,” said Dr. Andrea Pfeifer, CEO of AC Immune. “This agreement allows us to leverage the developmental expertise, strategic vision and financial capacity of an accomplished organization that has demonstrated its ability to execute the type of comprehensive global program required for Phase 3 trials in Alzheimer’s disease while allowing us to focus on completing Phase 1b/2 development and accelerating our efforts to replicate this success with enhanced funding for our early-stage pipeline.”

AC Immune will be responsible for completing the ABATE trial. Following option exercise, Takeda would conduct and fund all further clinical development and be responsible for all global regulatory activities as well as worldwide commercialization.

“At Takeda, we are committed to tackling some of society’s most debilitating illnesses, including Alzheimer’s disease. We are excited to partner with AC Immune on this ground-breaking treatment approach, which leverages novel technology with the potential to offer patients a treatment with differentiated efficacy, safety and ease of administration,” said Sarah Sheikh, M.Sc., B.M., B.Ch, MRCP, Head, Neuroscience Therapeutic Area Unit and Head, Global Development at Takeda. “Combining AC Immune’s deep experience with active immunotherapy approaches with Takeda’s expertise in neuroscience drug development and commercialization, we have an incredible opportunity to deliver real impact to the Alzheimer’s community.”

Under the terms of the agreement, AC Immune will receive an upfront payment of $100 million and be eligible to receive an option exercise fee and additional potential development, commercial and sales-based milestones of up to approximately $2.1 billion if all related milestones are achieved over the course of the agreement. Upon commercialization, AC Immune will be entitled to receive tiered double-digit royalties on worldwide net sales.

Further details related to the agreement are available in the Form 6-K filed today by AC Immune with the U.S. Securities and Exchange Commission (SEC). The effectiveness of Takeda's license following option exercise is subject to the termination or expiration of any applicable waiting periods under the Hart-Scott-Rodino Act.

Conference Call and Webcast Information

AC Immune management will host a conference call and webcast today at 8:30 a.m. ET to provide a brief overview of the agreement.

Monday, May 13 at 8:30 a.m. ET 
Participants wishing to ask questions or to join the event via phone may call the following numbers 10 – 15 minutes before conference start:

United States

+1 (1) 631 570 56 13

Switzerland / Europe

+41 (0) 58 310 50 00

United Kingdom

+44 (0) 207 107 06 13

Other international numbers available

HERE

 

责任编辑:admin

相关阅读

天猫网友:念成疾 crize
评论:我能想到最浪漫的事,就是看你一起慢慢变老,而我依然青春年少.

其它网友:涐哭谁心疼╮
评论:小时候,只有有人一直盯着我我就会脸红。现在,只要有人盯着我,我就会让他脸红。

凤凰网友:夏花一般绚烂
评论:我其实是个天使,之所以留在人间,是因为体重的关系

百度网友:霸气的小乞丐
评论:在身材这个问题上,我是坚决不会承认自己是一个粗人的。

天涯网友:她有我保护
评论:在如今这个物价飞涨的时代,只有工资以不变应万变

猫扑网友:记得牵绊的人
评论:活在自己的心里,不要活在别人的眼里。

本网网友:安于此生ˉ2c1
评论:人生如同故事,重要的并不是有多长,而是在有多好。

搜狐网友:人身尽情挥霍
评论:我妈就生了这么一个限量版的我,你看着办吧Q_Q

淘宝网友:光棍节的忧伤
评论:天气热得像个笑话,日子过得像句废话。

腾讯网友:错过的情人
评论:你复杂的五官,掩饰不了你朴素的智商。